Healthcare / Medical DevicesStockholm
$7.74
-0.24 (-3.01%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-36.5M · quality 64.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$206M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-17.3%
↓Gross Margin
82.7%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.8%
FCF CAGR
—
FCF margin
-55.1%
FCF / Net income
1.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $91.1M · net income $-30.8M · FCF $-50.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $91.1M | $91.1M | $104.1M | $74.3M | $55.7M |
| Net Income | $-30.8M | $-30.8M | $4.0M | $-16.2M | $21.3M |
| EBITDA | $-35.2M | $-35.2M | $8.8M | $-20.4M | $2.5M |
| EPS | -1.50 | -1.50 | 0.22 | -0.87 | 1.16 |
| Gross Margin | 82.7% | 82.7% | 87.7% | 81.9% | 83.6% |
| Operating Margin | -45.6% | -45.6% | 0.7% | -34.0% | -13.4% |
| Net Margin | -33.8% | -33.8% | 3.9% | -21.8% | 38.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.04 | 0.06 | 0.00 |
| Current Ratio | 4.40 | 4.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-50.2M | $-50.2M | $-24.4M | $-36.5M | $-49.5M |
| Returns | |||||
| ROE | -17.3% | -17.3% | 2.8% | -11.3% | 13.3% |
| Valuation | |||||
| P/E | — | — | 255.04 | — | 34.97 |
| EV/EBITDA | — | — | 122.27 | — | 271.18 |
| P/B | 0.90 | 0.90 | 7.58 | 3.23 | 4.65 |
| Growth & Yield | |||||
| Revenue Growth | -12.5% | -12.5% | 40.2% | 33.3% | — |
| EPS Growth | -790.9% | -790.9% | 125.0% | -175.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-54.7%
Start / end P/E
n/dx → n/dx
EPS bridge
0.22 → -1.50
Residual
-54.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.